About: Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells
Creator	Arakawa, Takeshi Iijima, Masumi Jeong, Seong-Yun Jung, Joohee Matsuo, Hidenori Niimi, Tomoaki Sewaki, Tomomitsu Yoshimoto, Nobuo Choi, Eun Ichi Kuroda, Shun
Source	Medline; PMC
abstract	Dendritic cells (DCs) are key regulators of adaptive T-cell responses. By capturing exogenous antigens and presenting antigen-derived peptides via major histocompatibility complex molecules to naïve T cells, DCs induce antigen-specific immune responses in vivo. In order to induce effective host immune responses, active delivery of exogenous antigens to DCs is considered important for future vaccine development. We recently generated bionanocapsules (BNCs) consisting of hepatitis B virus surface antigens that mediate stringent in vivo cell targeting and efficient endosomal escape, and after the fusion with liposomes (LP) containing therapeutic materials, the BNC-LP complexes deliver them to human liver-derived tissues in vivo. BNCs were further modified to present the immunoglobulin G (IgG) Fc-interacting domain (Z domain) derived from Staphylococcus aureus protein A in tandem. When mixed with IgGs, modified BNCs (ZZ-BNCs) displayed the IgG Fv regions outwardly for efficient binding to antigens in an oriented-immobilization manner. Due to the affinity of the displayed IgGs, the IgG-ZZ-BNC complexes accumulated in specific cells and tissues in vitro and in vivo. After mixing ZZ-BNCs with antibodies against DCs, we used immunocytochemistry to examine which antibodies delivered ZZ-BNCs to mouse splenic DCs following intravenous injection of the ZZ-BNCs. ZZ-BNCs displaying anti-CD11c monoclonal antibodies (α-CD11c-ZZ-BNCs) were found to accumulate with approximately 62% of splenic DCs, and reside within some of them. After the fusion with liposomes containing antigens, the α-CD11c-ZZ-BNCs could elicit the respective antibodies more efficiently than other nontargeting control vaccines, suggesting that this DC-specific nanocarrier is promising for future vaccines.
has issue date	2012-07-03(xsd:dateTime)
bibo:doi	10.2147/ijn.s32813
bibo:pmid	22848163
has license	no-cc
sha1sum (hex)	d6a5a00ad9468ae27a3a1c7cc33c2131297fbaa9
schema:url	https://doi.org/10.2147/ijn.s32813
resource representing a document's title	Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells
has PubMed Central identifier	PMC3405891
has PubMed identifier	22848163
schema:publication	Int J Nanomedicine
resource representing a document's body	covid:d6a5a00ad9468ae27a3a1c7cc33c2131297fbaa9#body_text
is schema:about of	named entity 'IN VIVO' named entity 'COMPLEXES' named entity 'MIXING' named entity 'REGULATORS' named entity 'DUE TO' named entity 'ESCAPE' named entity 'T-CELL' named entity 'FUSION' named entity 'INTRAVENOUS INJECTION' named entity 'RESIDE' named entity 'APPROXIMATELY' named entity 'RESPONSES' named entity 'SPECIFIC' named entity 'EFFECTIVE' named entity 'TISSUES' named entity 'MIXED' named entity 'INDUCE' named entity 'EFFICIENT' named entity 'MATERIALS' named entity 'ADAPTIVE' named entity 'REGIONS' named entity 'ELICIT' named entity 'EXOGENOUS' named entity 'derived' named entity 'antibodies' named entity 'antibodies' named entity 'antigens' named entity 'surface' named entity 'vivo' named entity 'human' named entity 'binding' named entity 'molecules' named entity 'surface' named entity 'ANTIGEN L' named entity 'ACTIVE TARGETING' named entity 'DENDRITIC CELLS' named entity 'IN VIVO' named entity 'ANTIBODIES' named entity 'HEPATITIS B VIRUS SURFACE ANTIGEN' named entity 'SPLENIC' named entity 'ENGINEERED' named entity 'IMMUNOGLOBULIN G' named entity 'THERAPEUTIC' named entity 'ANTIGEN' named entity 'VACCINE DEVELOPMENT' named entity 'AFFINITY' named entity 'ORDER' named entity 'CD11C' named entity 'DERIVED' named entity 'FOLLOWING' named entity 'CONTAINING' named entity 'MODIFIED' named entity 'PRESENTING' named entity 'TARGETING' named entity 'SPLENIC' named entity 'IMMOBILIZATION' named entity 'STAPHYLOCOCCUS AUREUS PROTEIN A' named entity 'MOUSE' named entity 'ANTIGENS' named entity 'TO EXAMINE' named entity 'TANDEM' named entity 'PROTEIN ' named entity 'IN VITRO' named entity 'CONTROL' named entity 'ACCUMULATED' named entity 'MOLECULES' named entity 'CONSIDERED' named entity 'DOMAIN' named entity 'CELLS' named entity 'PEPTIDES' named entity 'IMPORTANT' named entity 'RECENTLY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software